Page 1

February 2 , 2021 biotechne Bio - Techne Releases Second Quarter Fiscal 2021 Results MINNEAPOLIS , Feb. 2 , 2021 / PRNewswire / -- Bio - Techne Corporation ( NASDAQ : TECH ) today reported its financial results for the second quarter ended December 31 , 2020 . Second Quarter FY2021 Snapshot • Second quarter organic revenue increased by 19 % ( 21 % reported ) to $ 224.3 million and 15 % ( 16 % reported ) in the first half of fiscal 2021 to $ 428.5 million . • GAAP EPS was $ 1.15 versus $ 3.02 one year ago primarily relating to a non - recurring gain of approximately $ 121 million in our ChemoCentryx investment in the second quarter of fiscal 2020. Delivered record adjusted earnings per share ( EPS ) of $ 1.62 versus $ 1.08 one year ago . • Adjusted Operating Margin increased to 38.7 % in the second quarter of fiscal 2021 compared to 33.4 % in the second quarter of fiscal 2020 . • Excellent commercial execution in both the Protein Sciences and Diagnostics and Genomics segments , with each delivering record organic growth of 19 % . • Delivered record operating cash flows in the first half of fiscal 2021 while paying down approximately $ 125 million in outstanding debt . The Company's financial statements are prepared in accordance with accounting principles generally accepted in the United States ( GAAP ) . Adjusted EPS , adjusted earnings , adjusted gross margin , adjusted operating income , organic growth , and adjusted operating margin are non - GAAP measures that exclude certain items detailed later in this press release under the heading " Use of non - GAAP Adjusted Financial Measures . " A reconciliation of GAAP to non- GAAP financial measures is included in this press release . " I would like to thank the entire global Bio - Techne team for delivering such a stellar quarter , " said Chuck Kummeth , President and Chief Executive Officer of Bio - Techne . " To achieve 19 % organic growth , with only 3 % attributed to Covid tailwinds , attests to the strong execution of our strategy we have implemented in recent years . It's great to see this planning succeed in virtually all areas of our business . We delivered this organic growth with a continued focus on profitability , as our adjusted operating margin improved over 500 basis points year over year to 38.7 % . " Kummeth added , " The continued ramp of our high - growth platforms including Exosome Dx , Cell and Gene Therapy , GMP Proteins , proteomics instrumentation and genomics will be exciting to watch as we strive for continued double - digit organic growth . Our expanded digital platform , increased global brand presence , and world class customer relationships has brought our renowned protein and antibody products ( as well as our new platforms ) to the forefront of the life science tools and diagnostics industry . " Second Quarter Fiscal 2021